Metrion Biosciences

Metrion Biosciences listed in The Sunday Times 100 Tech, as one of Britain’s fastest-growing private technology companies

Inaugural feature recognises companies within the UK technology sector, developing or selling a proprietary technology Listing is recognition of Metrion’s leadership position in preclinical ion channel drug discovery research services 20 January 2025 – Cambridge, UK – Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today...

Axiogenesis and Metrion Biosciences announce stem cell collaboration

Cologne, Germany and Cambridge, UK, 07 November 2016: Axiogenesis AG, a preclinical biotechnology company specialising in the development and production of induced pluripotent stem cell (iPSC)-derived cells and tissues for preclinical applications, and Metrion Biosciences Ltd, the specialist ion channel CRO, have signed a collaboration agreement to validate, optimise and commercialise iPSC-derived cell based assays...

Metrion Biosciences Expands Operations

Moves to new Laboratories at Granta Park, Cambridge Appoints Dr Andrew Southan as Head of Commercial Operations Cambridge, UK, 17 October 2016: Metrion Biosciences, the specialist ion channel CRO, today announced it has moved into new, larger laboratories at Granta Park, Cambridge, and appointed Dr Andrew Southan as Head of Commercial Operations. Metrionís move to...

Metrion Biosciences Joins CRACK IT DRGNET Human Pain Research Consortium

Cambridge, UK, 23 August 2016: Metrion Biosciences Ltd ('Metrion'), the specialist ion-channel and drug discovery CRO, has entered into an agreement with a network of partners to evaluate the use of primary human dorsal root ganglion (hDRG) neurons in pain research. This Consortium comprises the University of Glasgow ('the University'), the University of St Andrews,...
Metrion Biosciences Building, B501 Babraham, Research Campus, Cambridge, CB22 3AT, UK

+44 (0) 1223 919 100